# Report: 11_OPC_like_1 (run_2.md)

**Cell type:** malignant glioblastoma cells
**Disease:** glioblastoma multiforme (IDH wildtype)
**Tissue:** brain

## Program Summaries
### Extracellular Matrix Remodeling and Cell Adhesion
This program encompasses genes encoding structural proteins, proteoglycans, and adhesion molecules that compose and remodel the glioblastoma extracellular matrix. The ECM serves as an active mediator of tumor invasion, immune cell infiltration, and therapeutic resistance through dynamic interactions with tumor and stromal cells. Components include collagen crosslinkers, matricellular proteins, and glycoproteins that facilitate cell-cell contact and cell-matrix interactions critical for GBM progression.

**Predicted impacts:**
- Enhanced ECM-mediated tumor cell invasion through sinuous brain tissue
- Increased cell-cell contact adhesion promoting collective invasion
- Altered leukocyte infiltration and immune suppression through ECM remodeling
- Sustained proliferative signaling via integrin-ECM crosstalk
- Therapeutic resistance through altered drug penetration in dense ECM

**Supporting genes:** COL4A3, COL4A4, COL20A1, TNR, SMOC1, ALCAM, PCDH15, MEGF11, THSD4, LAMB4, ADAMTS17, ITGA9, FERMT1, LRRC7, TNS3, LRFN5

**References:** [34], [5], [7]

**Biological processes:**
- collagen fibril assembly and crosslinking: COL4A3, COL4A4, COL20A1, ADAMTS17
- cell adhesion molecule expression and function: ALCAM, PCDH15, MEGF11, LRFN5
- matricellular protein interactions: SMOC1, TNR, THSD4, LAMB4
- integrin-ECM interaction and signaling: ITGA9, FERMT1

**Cellular components:**
- extracellular matrix scaffold: COL4A3, COL4A4, COL20A1, TNR, SMOC1
- adhesion complex organization: ALCAM, PCDH15, LRRC7, TNS3

**Reference notes:**
- Systematic review on ECM modifications in GBM showing active role in tumor development and microenvironment shaping
- Review on leveraging ECM to increase immunotherapy efficacy through understanding ECM-immune cell interactions
- Recent study (2025) demonstrating ECM-integrin interactions as therapeutic target in GBM

### Ion Channel-Mediated Cell Motility
This program integrates ion channels and transporters that regulate cellular ion homeostasis, membrane potential, and cell volume dynamics essential for glioblastoma migration and invasion. Potassium, calcium, chloride, and sodium channels modulate cell cycle progression and facilitate the morphological changes necessary for cells to navigate through constrained brain tissue spaces. Dysregulation of these channels contributes to the extensive invasive migration characteristic of GBM.

**Predicted impacts:**
- Facilitated cell cycle progression through G1/S and G2/M checkpoints
- Enhanced invasive cell migration through rapid morphological transitions
- Improved survival under metabolic stress through pH buffering
- Increased cell volume dynamics enabling navigation through sinuous extracellular spaces
- Sustained proliferation via ion-dependent signaling amplification

**Supporting genes:** CACNA1E, TRPC4, KCNIP3, ANO3, ANO4, SLC8A3, SLC5A4, SLC26A7, CA10

**References:** [13], [4]

**Biological processes:**
- potassium channel activity and cell cycle regulation: KCNIP3
- calcium influx and signaling: CACNA1E, TRPC4
- chloride channel-mediated depolarization: ANO3, ANO4
- sodium transport and osmotic regulation: SLC8A3, SLC5A4
- pH regulation and acidification: CA10

**Cellular components:**
- ion channel complexes: CACNA1E, TRPC4, KCNIP3, ANO3, ANO4
- solute carrier transporters: SLC8A3, SLC5A4, SLC26A7

**Reference notes:**
- Comprehensive 2011 review on ion channels in glioblastoma detailing roles in proliferation, migration, and invasion
- Recent analysis of migration-associated transportome including SLC transporters in GBM

### Oligodendrocyte Lineage Progenitor Identity
This program comprises genes characterizing oligodendrocyte precursor cells (OPCs) and immature oligodendrocytes, cell types implicated as cells-of-origin for glioblastoma. These genes regulate cell fate determination, developmental progression, and maintenance of progenitor cell characteristics. The aberrant expression of OPC-associated genes in GBM reflects the developmental origin of these tumors and their heterogeneous cellular composition including pre-myelinating states.

**Predicted impacts:**
- Maintenance of progenitor cell state and self-renewal capacity
- Impaired terminal differentiation with retention of proliferative phenotype
- Activation of developmental programs associated with GBM stem cells
- Enhanced glioma stemness through aberrant OPC program expression
- Tumor heterogeneity driven by multiple OPC-derived cellular states

**Supporting genes:** BCAS1, SOX6, MYRF, MOG, OMG, CLDN11, EYA1

**References:** [10], [24], [40]

**Biological processes:**
- oligodendrocyte precursor cell specification and maintenance: SOX6, MYRF
- myelin gene regulation and terminal differentiation: MYRF, OMG, MOG
- immature oligodendrocyte marker expression: BCAS1, CLDN11

**Cellular components:**
- oligodendrocyte development transcription factor complex: SOX6, MYRF, EYA1
- oligodendrocyte membrane proteins: BCAS1, MOG, OMG, CLDN11

**Reference notes:**
- First comprehensive characterization of BCAS1 expression in diffuse gliomas showing correlation with tumor grade and proliferation
- Detailed mechanistic study of Myrf-Sox10 cooperation during oligodendrocyte development
- Identification of OLIG2 as most specific GSC marker demonstrating developmental origin of GBM

### Notch Signaling and Stem Cell Maintenance
This program encompasses genes controlling Notch pathway signaling that maintains glioma stem cell (GSC) self-renewal, stemness capacity, and resistance to differentiation. Delta-like ligands (DLL1, DLL3) and downstream effectors regulate the undifferentiated phenotype characteristic of GSCs. Dysregulation of Notch signaling is associated with poor prognosis and enhanced tumor aggressiveness in glioblastoma.

**Predicted impacts:**
- Sustained GSC self-renewal and reduced differentiation capacity
- Enhanced stem cell marker expression including CD133, nestin, SOX2, OCT4
- Increased resistance to apoptosis through Notch-AKT signaling
- Promoted epithelial-to-mesenchymal transition and invasion
- Improved survival under stress conditions through let-7 suppression

**Supporting genes:** DLL1, DLL3, LIN28B, MIR503HG, MIR217HG

**References:** [11], [14]

**Biological processes:**
- Delta-like ligand-mediated Notch activation: DLL1, DLL3
- stem cell self-renewal and stemness maintenance: DLL1, DLL3
- microRNA regulation of Notch pathway: LIN28B, MIR503HG, MIR217HG
- Notch-mediated EMT and invasion: DLL1, DLL3

**Cellular components:**
- Notch signaling receptor and ligand complex: DLL1, DLL3
- microRNA biogenesis and regulation: LIN28B, MIR503HG, MIR217HG

**Reference notes:**
- Comprehensive review of Notch signaling in GBM pathogenesis with emphasis on GSC maintenance and poor prognosis correlation
- Review on LIN28B and let-7 in diffuse midline glioma demonstrating LIN28B overexpression in GBM with poor survival

### Lipid Metabolism and Sphingolipid Remodeling
This program encompasses enzymes and transporters regulating lipid and sphingolipid metabolism, including fatty acid hydroxylation, glycosphingolipid synthesis, and ether lipid degradation. Dysregulated lipid metabolism in GBM contributes to altered membrane composition, enhanced proliferation, migration, and survival signaling. These metabolic alterations create distinct lipid signatures associated with aggressive GBM phenotypes.

**Predicted impacts:**
- Altered membrane fluidity and composition supporting enhanced proliferation
- Enhanced ceramide and hexosylceramide accumulation promoting survival signaling
- Increased arachidonic acid mobilization supporting inflammatory and pro-tumoral signals
- Modified glycosaminoglycan synthesis affecting ECM interactions and cell adhesion
- Altered immune cell recognition through lipid antigen modifications

**Supporting genes:** FA2H, UGT8, PLPP4, PLA2G4A, PLAAT1, AGMO, UGDH, GFPT2, CHST9, HS6ST2

**References:** [17], [26], [39]

**Biological processes:**
- fatty acid 2-hydroxylation: FA2H
- glycosphingolipid synthesis and glycosylation: UGT8, HS6ST2, CHST9
- phospholipid phosphatase activity: PLPP4
- ether lipid catabolism: AGMO
- phospholipase activity and arachidonic acid mobilization: PLA2G4A, PLAAT1
- UDP-sugar metabolism: UGDH, GFPT2

**Cellular components:**
- glycosphingolipid biosynthetic enzymes: FA2H, UGT8, CHST9, HS6ST2
- phospholipid remodeling enzymes: PLPP4, PLA2G4A, PLAAT1

**Reference notes:**
- PLPP4 as driver of malignant glioma progression with high expression correlating with clinicopathological features and poor survival
- FA2H and UGT8 transcript levels predicting hydroxylated hexosylceramide accumulation in cancer
- AGMO as emerging enzyme with roles in immune defense and cancer development

### Cell Migration and Invasion Machinery
This program integrates genes encoding proteins that directly facilitate glioblastoma cell motility, including cell migration regulators, cytoskeletal modulators, and axon guidance pathway components. These genes coordinate dynamic actin remodeling, cell-matrix interactions, and directional migration enabling GBM cells to infiltrate surrounding brain tissue. Dysregulation of this program drives the extensive invasion characteristic of GBM and is associated with therapeutic resistance.

**Predicted impacts:**
- Enhanced directional migration toward chemoattractants and away from repellents
- Sustained actin polymerization dynamics supporting morphological plasticity
- Improved focal adhesion formation and turnover enabling rapid migration
- Increased invasive potential through sinuous brain parenchyma
- Adaptation to hypoxic and acidic microenvironments during migration

**Supporting genes:** ELMO1, DOCK10, REPS2, LHFPL3-AS1, SLIT1, SEMA3E, KIF21B, LRRC7, TNS3, AFAP1L2, FERMT1

**References:** [16], [31], [35]

**Biological processes:**
- cell migration and motility regulation: ELMO1, DOCK10, REPS2, LHFPL3-AS1
- axon guidance and chemo-repulsion: SLIT1, SEMA3E
- actin cytoskeleton dynamics and organization: KIF21B, LRRC7, TNS3, AFAP1L2
- focal adhesion assembly and dynamics: TNS3, FERMT1

**Cellular components:**
- cell migration regulator proteins: ELMO1, DOCK10, REPS2
- actin regulatory complex: KIF21B, LRRC7, TNS3, AFAP1L2
- chemoattractive/chemorepulsive pathway components: SLIT1, SEMA3E

**Reference notes:**
- ELMO1 specifically identified in invasive areas of glioblastoma as central for cell migration
- KIF21b regulates actin cytoskeleton dynamics controlling nucleokinesis and branching during neuronal migration
- LHFPL3 involvement in GBM migration and invasion with EMT participation

### Growth Factor Receptor Signaling and Proliferation
This program integrates receptor tyrosine kinases, G protein-coupled receptors, and their associated signaling molecules that drive glioblastoma proliferation. These genes regulate growth factor-dependent cell cycle progression, survival signaling, and metabolic reprogramming. Dysregulation of this program through overexpression or constitutive activation drives unchecked GBM proliferation and is associated with aggressive disease and poor prognosis.

**Predicted impacts:**
- Sustained proliferation through growth factor-dependent cell cycle progression
- Enhanced survival signaling through multiple receptor pathways
- Increased metabolic flux supporting anabolic cell growth
- Amplified ERK and PI3K-AKT pathway activation
- Therapeutic resistance through receptor redundancy and pathway crosstalk

**Supporting genes:** AR, FGF12, VIPR2, ERBB3, TACR1, NRSN1, GPR17, CCND1

**References:** [21], [23], [8]

**Biological processes:**
- receptor tyrosine kinase signaling: FGF12, VIPR2, ERBB3
- androgen receptor-mediated proliferation: AR
- neuropeptide receptor signaling: TACR1, NRSN1
- cell cycle checkpoint progression: CCND1

**Cellular components:**
- receptor tyrosine kinase complexes: FGF12, ERBB3
- G protein-coupled receptor complexes: TACR1, VIPR2, GPR17
- steroid receptor signaling: AR

**Reference notes:**
- AR overexpression in GBM with demonstrated role in proliferation, migration, invasion, and therapeutic resistance
- FGFR4 overexpression in aggressive GBM subgroup with integrin-related resistance
- ERBB3 enrichment in CD133+ cancer stem cells as potential therapeutic target

### Mesenchymal Transition and Invasion Program
This program represents genes controlling epithelial-to-mesenchymal transition (EMT) and related developmental plasticity that drives glioblastoma's aggressive phenotype. These genes regulate the shift from adhesive epithelial-like states to migratory mesenchymal-like states, facilitating invasion and therapeutic resistance. Activation of this program is associated with poor prognosis, radiation resistance, and tumor recurrence.

**Predicted impacts:**
- Shift from adhesive to migratory phenotype
- Enhanced invasive capability and reduced differentiation
- Acquisition of stem cell characteristics and therapeutic resistance
- Increased survival under stress including hypoxia and acidic conditions
- Promotion of recurrent tumors with more aggressive phenotype

**Supporting genes:** LINC00689, NKD1, DISC1, LINC01268, LINC01322, CA10, EYA1, SOX6

**References:** [1], [48], [49]

**Biological processes:**
- epithelial-mesenchymal transition: LINC00689, NKD1, DISC1
- developmental reprogramming and cell fate plasticity: LINC00689, LINC01268, LINC01322
- hypoxia-driven phenotypic switching: CA10, LINC00689

**Cellular components:**
- developmental transcription factor networks: LINC00689, EYA1, SOX6

**Reference notes:**
- Comprehensive review of EMT in GBM progression showing radiation-associated EMT and acquisition of stem cell markers
- Hypoxia driving mesenchymal-like phenotype in invasive glioma stem cells with enhanced immune suppression
- Single-nucleus transcriptomics revealing multiple malignant cell states including developmental plasticity

### Mitochondrial Dynamics and Cellular Metabolism
This program integrates genes controlling mitochondrial function, energetics, and metabolic adaptation essential for GBM's high proliferative and invasive capacity. These genes regulate ATP production, lipid storage, and metabolic plasticity allowing GBM cells to survive under nutrient-poor and hypoxic conditions. Dysregulation of this program supports the Warburg effect and altered metabolic state characteristic of GBM.

**Predicted impacts:**
- Enhanced energy production supporting rapid proliferation and migration
- Metabolic flexibility allowing survival under hypoxia and nutrient deprivation
- Lipid accumulation in storage organelles providing energy reserves
- Enhanced radioresistance through altered mitochondrial lipid composition
- Resistance to energy-depleting therapeutic strategies

**Supporting genes:** DISC1, DGKB, ATP13A5, PLPP4, FA2H

**References:** [22], [32]

**Biological processes:**
- mitochondrial dynamics and bioenergetics: DISC1, DGKB
- lipid storage and energy metabolism: DGKB, PLPP4, FA2H
- proton pump-mediated metabolic stress: ATP13A5

**Cellular components:**
- mitochondrial protein import and organization: DISC1
- lipid metabolism and storage organelles: DGKB, PLPP4, FA2H
- proton gradient maintenance: ATP13A5

**Reference notes:**
- DGKB-DGAT1 axis demonstrating lipid metabolism control of radioresistance through mitochondrial lipotoxicity
- DISC1 role in mitochondrial dynamics affecting GBM cell development

### Proteolytic Processing and Proteasomal Activity
This program comprises genes encoding proteases and proteasomal components that regulate protein processing, cellular remodeling, and quality control in glioblastoma. These enzymes process pro-proteins into active forms, degrade regulatory proteins, and remodel the microenvironment. Dysregulation of proteolytic activity contributes to GBM invasion, immune evasion, and therapeutic resistance.

**Predicted impacts:**
- Enhanced ECM remodeling supporting invasion and migration
- Processing of pro-inflammatory mediators affecting microenvironment
- Immune evasion through altered antigen processing
- Increased therapeutic resistance through protease-mediated drug degradation
- Amplified growth factor signaling through pro-growth factor activation

**Supporting genes:** PCSK2, PRSS12, TMPRSS9

**References:** [29], [41]

**Biological processes:**
- proprotein convertase-mediated processing: PCSK2
- serine protease activity: PRSS12, TMPRSS9
- macrophage-mediated tumor immunity reactivation: PCSK2

**Cellular components:**
- serine protease complexes: PRSS12, TMPRSS9

**Reference notes:**
- Proprotein convertase inhibitor demonstrates dual anti-glioma and macrophage reactivation activity
- PRSS12 prognostic marker in glioblastoma multiforme

### Signal Transduction Modulation and cAMP/Calcium Signaling
This program encompasses genes regulating intracellular signal transduction, including phosphodiesterases, calcium signaling proteins, and kinase regulators that modulate cellular responses to growth factors, neuropeptides, and stress. These genes fine-tune signaling intensity and duration controlling proliferation, differentiation, and survival. Dysregulation of signal transduction creates sustained pro-tumoral signaling.

**Predicted impacts:**
- Sustained proliferative signaling through reduced second messenger turnover
- Enhanced growth factor responsiveness through cAMP/calcium modulation
- Increased invasive capacity through kinase-dependent cytoskeletal remodeling
- Altered differentiation responses through calcium signaling dysregulation
- Therapeutic resistance through signaling pathway redundancy

**Supporting genes:** PDE4A, PDE7B, PRKG2, CALCRL, ARPP21

**References:** [20]

**Biological processes:**
- phosphodiesterase-mediated cAMP and cGMP degradation: PDE4A, PDE7B, PRKG2
- calcium/calmodulin-dependent signaling: CALCRL, PRKG2
- kinase regulation and phosphorylation dynamics: ARPP21

**Cellular components:**
- phosphodiesterase enzyme complexes: PDE4A, PDE7B
- calcium regulatory proteins: CALCRL, PRKG2

**Reference notes:**
- Review on cAMP signaling in cancer showing impact on incidence and development

### Endosomal Recycling and Receptor Trafficking
This program integrates genes regulating endosomal membrane trafficking and receptor recycling that control cell surface receptor density and signaling duration. These genes mediate the balance between receptor recycling to the cell surface (sustaining signaling) versus degradation in lysosomes (attenuating signaling). Dysregulation of endosomal recycling in GBM promotes sustained growth factor signaling and therapeutic resistance.

**Predicted impacts:**
- Sustained EGFR and other RTK signaling through increased cell surface density
- Enhanced proliferative signaling via ERK and Akt pathway amplification
- Reduced responsiveness to growth factor withdrawal
- Therapeutic resistance to receptor-targeting drugs through increased surface density
- Increased invasive capacity via sustained signaling

**Supporting genes:** MYRIP, ATP13A5

**References:** [45]

**Biological processes:**
- endosomal recycling pathway regulation: MYRIP, ATP13A5
- receptor trafficking and subcellular localization: MYRIP

**Cellular components:**
- recycling endosome components: MYRIP, ATP13A5

**Reference notes:**
- Systematic computational analysis of endosomal recycling pathway in glioblastoma identifying dysregulated regulators and prognostic signature

## References
- [1] Notes: Single-nucleus transcriptomics revealing multiple malignant cell states including developmental plasticity
- [10] Notes: Identification of OLIG2 as most specific GSC marker demonstrating developmental origin of GBM
- [11] Notes: Comprehensive review of Notch signaling in GBM pathogenesis with emphasis on GSC maintenance and poor prognosis correlation
- [13] Notes: Recent analysis of migration-associated transportome including SLC transporters in GBM
- [14] Notes: Review on LIN28B and let-7 in diffuse midline glioma demonstrating LIN28B overexpression in GBM with poor survival
- [16] Notes: ELMO1 specifically identified in invasive areas of glioblastoma as central for cell migration
- [17] Notes: FA2H and UGT8 transcript levels predicting hydroxylated hexosylceramide accumulation in cancer
- [20] Notes: Review on cAMP signaling in cancer showing impact on incidence and development
- [21] Notes: AR overexpression in GBM with demonstrated role in proliferation, migration, invasion, and therapeutic resistance
- [22] Notes: DISC1 role in mitochondrial dynamics affecting GBM cell development
- [23] Notes: ERBB3 enrichment in CD133+ cancer stem cells as potential therapeutic target
- [24] Notes: Detailed mechanistic study of Myrf-Sox10 cooperation during oligodendrocyte development
- [26] Notes: PLPP4 as driver of malignant glioma progression with high expression correlating with clinicopathological features and poor survival
- [29] Notes: Proprotein convertase inhibitor demonstrates dual anti-glioma and macrophage reactivation activity
- [31] Notes: LHFPL3 involvement in GBM migration and invasion with EMT participation
- [32] Notes: DGKB-DGAT1 axis demonstrating lipid metabolism control of radioresistance through mitochondrial lipotoxicity
- [34] Notes: Review on leveraging ECM to increase immunotherapy efficacy through understanding ECM-immune cell interactions
- [35] Notes: KIF21b regulates actin cytoskeleton dynamics controlling nucleokinesis and branching during neuronal migration
- [39] Notes: AGMO as emerging enzyme with roles in immune defense and cancer development
- [4] Notes: Comprehensive 2011 review on ion channels in glioblastoma detailing roles in proliferation, migration, and invasion
- [40] Notes: First comprehensive characterization of BCAS1 expression in diffuse gliomas showing correlation with tumor grade and proliferation
- [41] Notes: PRSS12 prognostic marker in glioblastoma multiforme
- [45] Notes: Systematic computational analysis of endosomal recycling pathway in glioblastoma identifying dysregulated regulators and prognostic signature
- [48] Notes: Comprehensive review of EMT in GBM progression showing radiation-associated EMT and acquisition of stem cell markers
- [49] Notes: Hypoxia driving mesenchymal-like phenotype in invasive glioma stem cells with enhanced immune suppression
- [5] Notes: Systematic review on ECM modifications in GBM showing active role in tumor development and microenvironment shaping
- [7] Notes: Recent study (2025) demonstrating ECM-integrin interactions as therapeutic target in GBM
- [8] Notes: FGFR4 overexpression in aggressive GBM subgroup with integrin-related resistance
